RYSTIGGO DIN 02567067
Status: Approved
Holder: UCB CANADA INC
Health Canada record
| Active ingredient(s) | ROZANOLIXIZUMAB 420 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AL02 ROZANOLIXIZUMAB |
|---|
| Original market date | |
|---|
| Current status date | 31-Mar-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
UCB Canada Inc — licence 101597, currently licensed, last inspection rating C (2024-11-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ROZANOLIXIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02556081 | RYSTIGGO | UCB CANADA INC | Solution | ROZANOLIXIZUMAB 280 MG | Marketed |
| 02567075 | RYSTIGGO | UCB CANADA INC | Solution | ROZANOLIXIZUMAB 560 MG | Approved |
| 02567083 | RYSTIGGO | UCB CANADA INC | Solution | ROZANOLIXIZUMAB 840 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37245 | 2026-03-31 | Supplement to a New Drug Submission (SNDS) | New presentation |
Request a quote for RYSTIGGO
How to read a Canadian DIN record